Home Shop TRAIL-R2 (human):Fc (human), (recombinant)

TRAIL-R2 (human):Fc (human), (recombinant)

ALX-522-005

15 citations

Datasheet
Manual
SDS
CofA

Already have an account?

Shipping: Available products typically ship within 24/48h, via priority shipping.

Do you need support? Contact Customer Service or Technical Support.

Online Account
Access or Create Your Account

TRAIL-R2 (human):Fc (human), (recombinant) SDS-PAGE — Fig 1: SDS-PAGE Analysis. Lane 1: MW Marker, Lane 2: 1 µg, Lane 3: 2 µg TRAIL-R2.

TRAIL-R2 (human):Fc (human), (recombinant) ELISA — Fig 2: ELISA Analysis: 100 ng/well of receptor or control is coated on a 96-well plate. After blocking, ligand is titrated 2-fold in series, and detected with anti-flag antibody. TRAIL (Prod # ALX-522-003) shows positive for binding to TRAIL-R2 and negative for binding to either Fc control protein (Prod # ALX-203-004) and buffer control.

Product Details

Alternative Name	DR5, TNFRSF 10B, KILLER, CD262
Application Notes	ELISA: binds to TRAIL at 10-100 ng/ml.
Biological Activity	Inhibits human soluble TRAIL-mediated apoptosis.
Concentration	1mg/ml after reconstitution.
Endotoxin Content	<0.1EU/µg purified protein (LAL test; Bio Whittaker).
Formulation	Lyophilized. Contains PBS.
MW	58kDa (SDS-PAGE).
Purity	≥95% (SDS-PAGE)
Reconstitution	Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein.
Source	Produced in HEK 293 cells. The extracellular domain of human TRAIL-R2 (DR5) (aa 52-212) is fused to the Fc portion of human IgG1.
Specificity	Binds human and mouse TRAIL.
Technical Info / Product Notes	Historical data has shown inhibition of human soluble TRAIL-induced apoptosis in a concentration range of 0.5-10µg/ml.
UniProt ID	O14763

Handling & Storage

Use/Stability	Stable for at least 6 months after receipt when stored at -20°C.
Handling	Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
Long Term Storage	-20°C
Shipping	Blue Ice

Regulatory Status	RUO – Research Use Only

Proteasome inhibition triggers the formation of TRAIL receptor 2 platforms for caspase-8 activation that accumulate in the cytosol: Hellwig, C. T., Delgado, M. E., et al.; Cell Death Differ. 29, 147 (2022), Abstract
Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice: M.E. Guicciardi, et al.; Cell Death Dis. 8, 2535 (2017), Abstract — Full Text
Serine 574 phosphorylation alters transcriptional programming of FOXO3 by selectively enhancing apoptotic gene expression: Z. Li, et al.; Cell Death Differ. 23, 583 (2016), Abstract
Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels: J. Beyrath, et al.; Oncotarget 7, 64942 (2016), Abstract — Full Text
Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8: M.A. Laussmann, et al.; Cell Death Differ. 18, 1584 (2011), Abstract
Death receptor 5 signaling promotes hepatocyte lipoapoptosis: S.C. Cazanave, et al.; J. Biol. Chem. 286, 39336 (2011), Abstract
Two adjacent trimeric fas ligands are required for fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003), Abstract — Full Text
Induction of TRAIL-mediated glioma cell death by human T cells: J. Dörr, et al.; J. Neuroimmunol. 122, 117 (2002), Abstract
Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells: J.D. Lunemann, et al.; J. Immunol. 168, 4881 (2002), Abstract — Full Text
Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand: G. Lu, et al.; J. Immunol. 168, 1831 (2002), Abstract — Full Text

Related Products

TRAIL-R2 (human):Fc (human), (recombinant) (FITC conjugate)

ALX-522-005F

10 citations

Alternative Name	DR5, TNFRSF 10B, KILLER, CD262
Purity	≥95% (SDS-PAGE)
Source	Produced in HEK 293 cells. The extracellular domain of human TRAIL-R2 (DR5) (aa 52-212) is fused to the Fc portion of human IgG1.

TRAIL, soluble (human) (recombinant) set

ALX-850-018

20 citations

Purity	≥95% (SDS-PAGE)

Control:Fc fusion protein (human), (recombinant)

ALX-203-004

Negative control for Fc chimeric proteins

11 citations

Alternative Name	Thy-1 (RLE mutant)
Purity	≥90% (SDS-PAGE)
Source	Produced in HEK 293 cells. The extracellular domain of mutated hThy-1, hThy-1 (RLE) (aa 20-130), is fused to the Fc portion of human IgG1. The integrin binding sequence RLD of hThy-1 has been changed to RLE abolishing the binding of integrins.

Datasheet, Manuals, SDS & CofA

Manuals And Inserts

Datasheet

Certificate of Analysis

Please enter the lot number as featured on the product label

Lot No. :

SDS

Enzo Life Science provides GHS Compliant SDS

If your language is not available please fill out the SDS request form

Your Cart

Your Cart

TRAIL-R2 (human):Fc (human), (recombinant)

ALX-522-005

Product Details

Handling & Storage

Datasheet, Manuals, SDS & CofA

Manuals And Inserts

Certificate of Analysis

SDS

Change Country

Tell us about You

Tell us about your paper

Tell us about You

Tell us about your project